Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
25-Dihydroxyvitamin D3 ((24S)-24
In CD4+CD25− T cells
Torcetrapib
C2HF3O2/c18-17(19)20-7-2-4-11(16(26)27)21-15(25)14-10(6-8-30-14)24-32(28
It inhibits proliferation of P388 leukemia cells with an IC50 value of 20 μg/ml
Axitinib Catalog No.:M11394-2 25-Dihydroxyvitamin D3 ((24S)-24Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet derived growth factor receptor (PDGF), thereby exerting an anti angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma. Product